BOSTON, MA--(Marketwired - Aug 1, 2016) - InspireMD, Inc.
(NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic protection systems (EPS), neurovascular
devices and thrombus management technologies, today announced the listing of the Company's 44,242,424 previously issued warrants
on the NYSE MKT (the "Exchange"). Beginning at the market open on August 1, 2016, the warrants will commence trading under
the ticker symbol "NSPR.WS."
On July 7, 2016, InspireMD
announced the closing of a public offering of approximately $14.6 million, which included the issuance of these 44,242,424
warrants. Each warrant entitles the holder to purchase one common share of InspireMD at an exercise price of $0.20 until
July 7, 2021.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic
protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of
distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard™), neurovascular, and
peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or
similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be
predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key
markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical
device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our
limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii)
the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital
raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information
about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the
Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web
site at http://www.sec.gov .The Company assumes no obligation to publicly update
or revise its forward-looking statements as a result of new information, future events or otherwise.